

Mirtazapine Disintegrating Formulation

♣ ORGANON

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 23.03.2020

 5.4
 01.10.2020
 50200-00016
 Date of first issue: 23.01.2015

SECTION 1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Mirtazapine Disintegrating Formulation

Manufacturer or supplier's details

Company name of supplier : Organon & Co.

Address : Avenida 16 de Septiembre No. 301

Xaltocan - Xochimilco Mexico 16090

Telephone : 52 55 57284444 Emergency telephone : 215-631-6999

E-mail address : EHSSTEWARD@organon.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

SECTION 2. HAZARDS IDENTIFICATION

GHS Classification

Acute toxicity (Oral) : Category 4

Reproductive toxicity : Category 2

Specific target organ toxicity

- repeated exposure (Oral)

Category 2 (Nervous system)

GHS label elements

Hazard pictograms





Signal Word : Warning

Hazard Statements : H302 Harmful if swallowed.

H361fd Suspected of damaging fertility. Suspected of damaging

the unborn child.

H373 May cause damage to organs (Nervous system) through

prolonged or repeated exposure if swallowed.

Precautionary Statements : Prevention:

P201 Obtain special instructions before use.

P202 Do not handle until all safety precautions have been read

and understood.

P260 Do not breathe dust.

P264 Wash skin thoroughly after handling.

P270 Do not eat, drink or smoke when using this product.

P280 Wear protective gloves/ protective clothing/ eye protection/

face protection.

Response:

P301 + P312 + P330 IF SWALLOWED: Call a POISON CENTER or doctor/ physician if you feel unwell. Rinse mouth. P308 + P313 IF exposed or concerned: Get medical advice/



Mirtazapine Disintegrating Formulation



Version Revision Date: SDS Number: Date of last issue: 23.03.2020 5.4 01.10.2020 50200-00016 Date of first issue: 23.01.2015

attention.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste dis-

posal plant.

Other hazards

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
(+/-)-1,2,3,4,10,14b-Hexahydro-2-	85650-52-8	>= 20 -< 30
methylpyrazino[2,1-a]pyrido[2,3-		
c][2]benzazepine		
Citric acid	77-92-9	>= 1 -< 5
Cellulose	9004-34-6	>= 1 -< 5
Magnesium stearate	557-04-0	>= 1 -< 5

SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical

advice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled : If inhaled, remove to fresh air.

Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty

of water.

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact : If in eyes, rinse well with water.

Get medical attention if irritation develops and persists.

If swallowed, DO NOT induce vomiting.

Get medical attention.

Rinse mouth thoroughly with water.

Never give anything by mouth to an unconscious person.

Most important symptoms

: Harmful if swallowed.

and effects, both acute and

Suspected of damaging fertility. Suspected of damaging the

delayed

unborn child.

May cause damage to organs through prolonged or repeated

exposure if swallowed.

Contact with dust can cause mechanical irritation or drying of



Mirtazapine Disintegrating Formulation



 Version
 Revision Date:
 SDS Number:
 Date of last issue: 23.03.2020

 5.4
 01.10.2020
 50200-00016
 Date of first issue: 23.01.2015

the skin.

Dust contact with the eyes can lead to mechanical irritation.

Protection of first-aiders : First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical None known.

Unsuitable extinguishing

media

Specific hazards during fire

fighting

Avoid generating dust; fine dust dispersed in air in sufficient

concentrations, and in the presence of an ignition source is a

potential dust explosion hazard.

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod-

ucts

Carbon oxides

Nitrogen oxides (NOx)

Metal oxides

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment.

Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

Special protective equipment

for fire-fighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protec- :

tive equipment and emer-

gency procedures

Use personal protective equipment.

Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up

Sweep up or vacuum up spillage and collect in suitable

container for disposal.

Avoid dispersal of dust in the air (i.e., clearing dust surfaces

with compressed air).

Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items

employed in the cleanup of releases. You will need to



Mirtazapine Disintegrating Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 23.03.2020

 5.4
 01.10.2020
 50200-00016
 Date of first issue: 23.01.2015

determine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures : Static electricity may accumulate and ignite suspended dust

causing an explosion.

Provide adequate precautions, such as electrical grounding

and bonding, or inert atmospheres.

Local/Total ventilation

Use only with adequate ventilation.

Advice on safe handling : Do not breathe dust.

Do not swallow.

Avoid contact with eyes.

Avoid prolonged or repeated contact with skin.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure

assessment

Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition.

Take precautionary measures against static discharges. Do not eat, drink or smoke when using this product.

Take care to prevent spills, waste and minimize release to the

environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working

place.

When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

Conditions for safe storage : Keep in properly labeled containers.

Store locked up.

Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:

Strong oxidizing agents

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
(+/-)-1,2,3,4,10,14b- Hexahydro-2- methylpyrazino[2,1- a]pyrido[2,3-c][2]benzazepine	85650-52-8	TWA	25 μg/m³	Internal
		Wipe limit	250 µg/100 cm ²	Internal
Cellulose	9004-34-6	VLE-PPT	10 mg/m³	NOM-010- STPS-2014
		TWA	10 mg/m ³	ACGIH
Magnesium stearate	557-04-0	VLE-PPT	10 mg/m ³	NOM-010-



Mirtazapine Disintegrating Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 23.03.2020

 5.4
 01.10.2020
 50200-00016
 Date of first issue: 23.01.2015

		STPS-2014
TWA (Inhalable particulate matter)	10 mg/m³	ACGIH
TWA (Respirable particulate matter)	3 mg/m³	ACGIH

Engineering measures : Ensure adequate ventilation, especially in confined areas.

Minimize workplace exposure concentrations. Apply measures to prevent dust explosions.

Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment).

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or

exposure assessment demonstrates exposures outside the

recommended guidelines, use respiratory protection.

Filter type

Hand protection

Particulates type

Material : Chemical-resistant gloves

Remarks : Choose gloves to protect hands against chemicals depending

on the concentration specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before

breaks and at the end of workday.

Eye protection : Wear the following personal protective equipment:

Safety goggles

Skin and body protection : Select appropriate protective clothing based on chemical

resistance data and an assessment of the local exposure

potential.

Skin contact must be avoided by using impervious protective

clothing (gloves, aprons, boots, etc).

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : powder

Color : No data available

Odor : No data available

Odor Threshold : No data available

pH : No data available

Melting point/freezing point : No data available



Mirtazapine Disintegrating Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 23.03.2020

 5.4
 01.10.2020
 50200-00016
 Date of first issue: 23.01.2015

Initial boiling point and boiling

range

No data available

Flash point : No data available

Evaporation rate : No data available

Flammability (solid, gas) : May form explosive dust-air mixture during processing,

handling or other means.

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapor pressure : No data available

Relative vapor density : No data available

Density : No data available

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-

octanol/water

No data available

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, dynamic : No data available

Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle size : No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard. Chemical stability : Stable under normal conditions.

Possibility of hazardous reac-

tions

May form explosive dust-air mixture during processing,

handling or other means.



Mirtazapine Disintegrating Formulation



Version Revision Date: SDS Number: Date of last issue: 23.03.2020 5.4 01.10.2020 50200-00016 Date of first issue: 23.01.2015

Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks.

Avoid dust formation. Oxidizing agents

Incompatible materials

Hazardous decomposition

products

: No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Inhalation Skin contact Ingestion Eye contact

Acute toxicity

Harmful if swallowed.

Product:

Acute oral toxicity : Acute toxicity estimate: 1,588 mg/kg

Method: Calculation method

Components:

(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:

Acute oral toxicity : LD50 (Rat): 320 - 490 mg/kg

Citric acid:

Acute oral toxicity : LD50 (Mouse): 5,400 mg/kg

Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg

Method: OECD Test Guideline 402

Assessment: The substance or mixture has no acute dermal

toxicity

Cellulose:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Magnesium stearate:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg

Method: OECD Test Guideline 423

Assessment: The substance or mixture has no acute oral tox-

icity

Remarks: Based on data from similar materials



Mirtazapine Disintegrating Formulation



 Version
 Revision Date:
 SDS Number:
 Date of last issue: 23.03.2020

 5.4
 01.10.2020
 50200-00016
 Date of first issue: 23.01.2015

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Remarks: Based on data from similar materials

Skin corrosion/irritation

Not classified based on available information.

Components:

Citric acid:

Species : Rabbit

Method : OECD Test Guideline 404

Result : No skin irritation

Magnesium stearate:

Species : Rabbit

Result : No skin irritation

Remarks : Based on data from similar materials

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Citric acid:

Species : Rabbit

Result : Irritation to eyes, reversing within 21 days

Method : OECD Test Guideline 405

Magnesium stearate:

Species : Rabbit

Result : No eye irritation

Remarks : Based on data from similar materials

Respiratory or skin sensitization

Skin sensitization

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Components:

Magnesium stearate:

Test Type : Maximization Test Routes of exposure : Skin contact Species : Guinea pig

Method : OECD Test Guideline 406

Result : negative

Remarks : Based on data from similar materials



Mirtazapine Disintegrating Formulation

♣ ORGANON

Version Revision Date: SDS Number: Date of last issue: 23.03.2020 5.4 01.10.2020 50200-00016 Date of first issue: 23.01.2015

Germ cell mutagenicity

Not classified based on available information.

Components:

(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Test system: Chinese hamster lung cells

Result: negative

Test Type: unscheduled DNA synthesis assay

Test system: mammalian cells

Result: negative

Test Type: sister chromatid exchange assay

Test system: mammalian cells

Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test

Species: Rat

Cell type: Bone marrow Application Route: Oral Result: negative

Result. Hegative

Citric acid:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: in vitro micronucleus test

Result: positive

Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow

cytogenetic test, chromosomal analysis)

Species: Rat

Application Route: Ingestion

Result: negative

Cellulose:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse

Application Route: Ingestion



Mirtazapine Disintegrating Formulation

Version Revision Date: SDS Number: Date of last issue: 23.03.2020 50.4 01.10.2020 50200-00016 Date of first issue: 23.01.2015

Result: negative

Magnesium stearate:

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test

Result: negative

Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro

Method: OECD Test Guideline 473

Result: negative

Remarks: Based on data from similar materials

Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Remarks: Based on data from similar materials

Carcinogenicity

Not classified based on available information.

Components:

(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:

Species : Mouse Application Route : Oral

Exposure time : 18 month(s)

LOAEL : 200 mg/kg body weight

Result : equivocal Target Organs : Liver

Species : Rat
Application Route : Oral
Exposure time : 2 Years

LOAEL : 20 mg/kg body weight

Result : equivocal Target Organs : Liver, Thyroid

Cellulose:

Species : Rat
Application Route : Ingestion
Exposure time : 72 weeks
Result : negative

Reproductive toxicity

Suspected of damaging fertility. Suspected of damaging the unborn child.

Components:

(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:

Effects on fertility : Test Type: Fertility/early embryonic development

Species: Rat

Application Route: Oral

Fertility: LOAEL: 15 mg/kg body weight

Symptoms: Effect on estrous cycle, Increase of early resorp-



ORGANON

Mirtazapine Disintegrating Formulation

Version Revision Date: SDS Number: Date of last issue: 23.03.2020 5.4 01.10.2020 50200-00016 Date of first issue: 23.01.2015

tions.

Result: Animal testing did not show any effects on fertility., Embryotoxic effects and adverse effects on the offspring were

detected.

Effects on fetal development : Test Type: Development

Species: Rat

Application Route: Oral

Developmental Toxicity: LOAEL: 100 mg/kg body weight Result: Embryotoxic effects and adverse effects on the offspring were detected., No teratogenic effects.

Test Type: Development

Species: Rabbit Application Route: Oral

Developmental Toxicity: NOAEL: 40 mg/kg body weight Result: No adverse effects., No teratogenic effects.

Reproductive toxicity - As-

sessment

Some evidence of adverse effects on sexual function and fertility, based on animal experiments., Some evidence of

adverse effects on development, based on animal

experiments.

Citric acid:

Effects on fetal development : Test Type: One-generation reproduction toxicity study

Species: Rat

Application Route: Ingestion

Result: negative

Cellulose:

Effects on fertility : Test Type: One-generation reproduction toxicity study

Species: Rat

Application Route: Ingestion

Result: negative

Effects on fetal development : Test Type: Fertility/early embryonic development

Species: Rat

Application Route: Ingestion

Result: negative

Magnesium stearate:

Effects on fertility : Test Type: Combined repeated dose toxicity study with the

reproduction/developmental toxicity screening test

Species: Rat

Application Route: Ingestion Method: OECD Test Guideline 422

Result: negative

Remarks: Based on data from similar materials

Effects on fetal development : Test Type: Embryo-fetal development

Species: Rat

Application Route: Ingestion

Result: negative



Mirtazapine Disintegrating Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 23.03.2020

 5.4
 01.10.2020
 50200-00016
 Date of first issue: 23.01.2015

Remarks: Based on data from similar materials

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

May cause damage to organs (Nervous system) through prolonged or repeated exposure if swallowed.

Components:

(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:

Routes of exposure : Ingestion

Target Organs : Nervous system

Assessment : May cause damage to organs through prolonged or repeated

exposure.

Repeated dose toxicity

Components:

(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:

Species : Rat
LOAEL : 120 mg/kg
Application Route : Oral
Exposure time : 13 Weeks
Target Organs : Nervous system

Species : Dog
LOAEL : 15 mg/kg
Application Route : Oral
Exposure time : 52 Weeks
Target Organs : Nervous system

Symptoms : Tremors

Species : Dog LOAEL : 20 mg/kg Application Route : Oral Exposure time : 13 Weeks

Target Organs : Nervous system, Testis

Symptoms : Tremors

Citric acid:

Species : Rat

NOAEL : 4,000 mg/kg LOAEL : 8,000 mg/kg Application Route : Ingestion Exposure time : 10 Days

Cellulose:

Species : Rat

NOAEL : >= 9,000 mg/kg

Application Route : Ingestion



Mirtazapine Disintegrating Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 23.03.2020

 5.4
 01.10.2020
 50200-00016
 Date of first issue: 23.01.2015

Exposure time : 90 Days

Magnesium stearate:

Species : Rat

NOAEL : > 100 mg/kg
Application Route : Ingestion
Exposure time : 90 Days

Remarks : Based on data from similar materials

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:

Ingestion : Symptoms: Drowsiness, constipation, dry mouth, asthenia,

Dizziness, Disorientation

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): 6.92 mg/l

Exposure time: 96 h Method: FDA 4.11

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 19.5 mg/l

Exposure time: 48 h

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): 5.7

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 3.2

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Toxicity to fish (Chronic tox-

icity)

NOEC (Pimephales promelas (fathead minnow)): 3.6 mg/l

Exposure time: 31 d

Method: OECD Test Guideline 210

Toxicity to daphnia and other :

aquatic invertebrates (Chron-

ic toxicity)

NOEC (Daphnia magna (Water flea)): 0.32 mg/l

Exposure time: 21 d

Method: OECD Test Guideline 211

Toxicity to microorganisms : EC50 (Natural microorganism): > 1,000 mg/l

Exposure time: 3 h



Mirtazapine Disintegrating Formulation



Version Revision Date: SDS Number: Date of last issue: 23.03.2020 5.4 01.10.2020 50200-00016 Date of first issue: 23.01.2015

Test Type: Respiration inhibition Method: OECD Test Guideline 209

NOEC (Natural microorganism): < 100 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

Citric acid:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 100 mg/l

Exposure time: 96 h

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 1,535 mg/l

Exposure time: 24 h

Cellulose:

Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l

Exposure time: 48 h

Remarks: Based on data from similar materials

Magnesium stearate:

Toxicity to fish : LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l

Exposure time: 48 h Method: DIN 38412

Remarks: Based on data from similar materials

Toxicity to daphnia and other :

aquatic invertebrates

EL50 (Daphnia magna (Water flea)): > 1 mg/l

Exposure time: 47 h

Test substance: Water Accommodated Fraction Method: Directive 67/548/EEC, Annex V, C.2. Remarks: Based on data from similar materials

No toxicity at the limit of solubility.

Toxicity to algae/aquatic

plants

EL50 (Pseudokirchneriella subcapitata (green algae)): > 1

mg/l

Exposure time: 72 h

Test substance: Water Accommodated Fraction

Method: OECD Test Guideline 201

Remarks: Based on data from similar materials

No toxicity at the limit of solubility.

NOELR (Pseudokirchneriella subcapitata (green algae)): > 1

mg/l

Exposure time: 72 h

Test substance: Water Accommodated Fraction

Method: OECD Test Guideline 201

Remarks: Based on data from similar materials

Toxicity to microorganisms : EC10 (Pseudomonas putida): > 100 mg/l

Exposure time: 16 h

Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials



Mirtazapine Disintegrating Formulation



Version Revision Date: SDS Number: Date of last issue: 23.03.2020 50.4 01.10.2020 50200-00016 Date of first issue: 23.01.2015

Persistence and degradability

Components:

Citric acid:

Biodegradability : Result: Readily biodegradable.

Biodegradation: 97 % Exposure time: 28 d

Method: OECD Test Guideline 301B

Cellulose:

Biodegradability : Result: Readily biodegradable.

Magnesium stearate:

Biodegradability : Result: Not biodegradable.

Remarks: Based on data from similar materials

Bioaccumulative potential

Components:

(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:

Bioaccumulation : Species: Oncorhynchus mykiss (rainbow trout)

Bioconcentration factor (BCF): 334 Method: OECD Test Guideline 305

Partition coefficient: n-

octanol/water

log Pow: 2.78

Citric acid:

Partition coefficient: n-

octanol/water

log Pow: -1.72

Magnesium stearate:

Partition coefficient: n-

octanol/water

log Pow: > 4

Mobility in soil

Components:

(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:

Distribution among environ-

mental compartments

: log Koc: 4.48

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste

handling site for recycling or disposal.



Mirtazapine Disintegrating Formulation

ORGANON

Version **Revision Date:** SDS Number: Date of last issue: 23.03.2020 01.10.2020 50200-00016 Date of first issue: 23.01.2015 5.4

If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation

NOM-002-SCT

Not regulated as a dangerous good

Special precautions for user

Not applicable

SECTION 15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

Federal Law for the control of chemical precursors,

essential chemical products and machinery for

producing capsules, tablets and pills.

Not applicable

The ingredients of this product are reported in the following inventories:

AICS not determined

DSL not determined

IECSC not determined

SECTION 16. OTHER INFORMATION

Full text of other abbreviations

ACGIH USA. ACGIH Threshold Limit Values (TLV)

NOM-010-STPS-2014 Mexico. Norm NOM-010-STPS-2014 on Chemicals Polluting

the Work Environment - Identification, Assessment and Con-

trol - Appendix 1 Occupational Exposure Limits

ACGIH / TWA 8-hour, time-weighted average

NOM-010-STPS-2014 / VLE- :

PPT

Time weighted average limit value



Mirtazapine Disintegrating Formulation

Version Revision Date: SDS Number: Date of last issue: 23.03.2020 5.4 01.10.2020 50200-00016 Date of first issue: 23.01.2015

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Sources of key data used to compile the Material Safety

Data Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

Revision Date : 01.10.2020

The information is considered as correct, but not exhaustive, and will be used only as a guide, which is based in the current knowledge of the substance or mixture, and is applicable to proper safety precautions for the product.

MX / Z8